Chemoradiotherapy with FOLFOX plus cetuximab in locally advanced oesophageal cancer: The GERCOR phase II trial ERaFOX.

Fiche publication


Date publication

mars 2016

Journal

European journal of cancer (Oxford, England : 1990)

Auteurs

Membres identifiés du Cancéropôle Est :
Mme POZET Astrid


Tous les auteurs :
Lledo G, Huguet F, Chibaudel B, Di Fiore F, Mineur L, Galais MP, Artru P, Blondin V, Dupuis O, Abdiche MS, Jovenin N, Pozet A, Bonnetain F, Attia M, Dahan L, de Gramont A

Résumé

To determine efficacy and toxicity of radiation therapy combined with oxaliplatin, 5-fluorouracil, and folinic acid (FOLFOX) and cetuximab in patients with locally advanced oesophageal cancer.

Mots clés

Antineoplastic Combined Chemotherapy Protocols, adverse effects, Cetuximab, administration & dosage, Chemoradiotherapy, adverse effects, Disease-Free Survival, Esophageal Neoplasms, mortality, Esophagogastric Junction, drug effects, Fluorouracil, administration & dosage, France, Humans, Kaplan-Meier Estimate, Leucovorin, administration & dosage, Neoplasm Staging, Organoplatinum Compounds, administration & dosage, Proportional Hazards Models, Prospective Studies, Radiotherapy Dosage, Time Factors, Treatment Outcome

Référence

Eur. J. Cancer. 2016 Mar;56:115-121